Cantor Fitzgerald reiterates Ascendis Pharma stock rating at overweight By Investing.com

FDA granted accelerated approval for Yuviwel (TransCon CNP) for achondroplasia with a wholesale acquisition cost of $498,000/year, prompting multiple price target increases (Stifel $332, Cantor $300 reiterated, RBC $275, BofA $262, Morgan Stanley $256). Cantor Fitzgerald models Q1 Yorvipath revenue at $231M (€204M) and forecasts 992 new scripts (-5.5% q/q vs 1,050 in Q4 2025), below FactSet consensus of $253M; sequential growth is expected to accelerate into Q2. Ascendis reports 87% gross margins and 98% revenue growth LTM, and analysts expect the company to turn profitable this year; potential monetization of a ~$200M priority review voucher adds incremental value. Mentions of the ITC case against Yuviwel represent a legal overhang but do not offset the positive commercial and analyst developments.

Analysis

A recent commercialization inflection creates outsized second-order pressure from payors and distribution channels: expect accelerated gross-to-net erosion as manufacturer-funded patient access programs and free drug shipments are used tactically to drive script growth. That dynamic will compress reported revenue in the near term while concealing underlying demand, producing a classic “earnings illusion” where top-line dips coexist with improving patient metrics and eventual revenue normalization over subsequent quarters.

Legal and exclusivity pathways are the asymmetric risks here. Injunctive or import-blocking outcomes would materially extend pricing power and downside protection, while adverse rulings or delayed enforcement compress the addressable window and force steeper discounting — these outcomes typically resolve on multi-quarter to multi-year timelines and can move valuation by several 10s of percent.

Sell-side positioning and volatility are likely to remain elevated around the next two company catalysts (quarterly results and early commercialization readouts). That creates a favorable environment for defined-risk option structures to capture upside from accelerating script trajectory while limiting downside to payer-driven troughs; conversely, owning naked equity exposes you to binary litigation and payor cadence risk without protection.

Key Decisions for Investors

• Buy a directional, defined-risk call spread on ASND (6–9 month expiration, 25–35% out-of-the-money strikes) sized to 2–3% of NAV. Rationale: captures upside from post-trough script acceleration and commercialization reacceleration with max loss = premium paid; target 2.0–3.5x return if uptake momentum reasserts within two quarters.
• Purchase protective puts on ASND (3–6 month, ~20% OTM) sized to 1% NAV as insurance against a negative litigation/access outcome. Rationale: limits downside from an adverse exclusivity ruling or sudden payor pullback; cost should be treated as insurance premium (target max drawdown protection to 30–40%).
• Pair trade: long ASND equity (1–2% NAV) vs short a broad small-cap biotech ETF (e.g., XBI) sized to neutralize beta. Rationale: isolates company-specific commercialization and litigation convexity while hedging sector volatility; unwind if sector breadth turns positive and ASND-specific fundamentals lag.
• Event play: accumulate small equity tranches into near-term earnings volatility windows and scale into any post-print weakness that shows improving patient-level metrics (scripts, refill rates). Hard stop: cut if sequential patient metrics decline for two consecutive quarters or if an adverse injunctive ruling is filed.